Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of zilovertamab vedotin + R-CHP versus polatuzumab vedotin + R-CHP in previously untreated GCB DLBCL
MOH_2025-04-01_013999Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Zilovertamab vedotin + R-CHP with Polatuzumab vedotin + R-CHP (2 arms). Primary endpoint: Complete response rate at end of treatment. Started Mar 2025; status: recruiting.
02
Drugs
zilovertamab vedotinpolatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2025-04-01_013999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-01_013999.